Diagnostic Services

Diagnostic Services – provides comprehensive clinical laboratory services across all major areas of clinical pathology, from routine screenings to advanced testing, supporting everything from disease prevention to treatment monitoring. Operations are carried out through a network of laboratories, blood-drawing points and clinics across 15 countries, with key markets in Germany, Romania and Poland.

Events in the quarter

• The IMD Laboratory Berlin has taken over a new, modern laboratory building on Siemensstraße, adjacent to its main site. The four‑storey facility will house microbiology, microbiome diagnostics and pathogen PCR in a shared, integrated setup.

• Medicover Integrated Clinical Services has signed a Memorandum of Understanding with GCCL Co., LTD., a data driven clinical trial service provider to strengthen multinational clinical trial capabilities across Europe, the U.S. and the Asia-Pacific region.

Revenue was EUR 200.3 million (EUR 182.2 million), an increase of 9.9%. Organic growth amounted to 7.2%, with price representing approximately 3.4pp of this growth.

Acquired revenue amounted to EUR 10.9 million, related to the acquisition of last year.

Foreign exchange fluctuations had a negative impact of 3.3% relating to weakness mainly of the Ukrainian hryvna.

FFS revenue increased across all key markets, supported by the acquisition completed in Q2 2025. Germany continued to demonstrate solid momentum in FFS. The impact of last year's reform is now fully embedded in the comparative base. Ukraine delivered strong growth in local currency, despite challenging operating conditions related to weather disruption and power outages. 

The laboratory test volume increased to 39.8 million (36.4 million), an increase of 9.5%, of which 8.7pp related to the acquisition from Q2 2025. 1.0 million (0.5 million) basic low-priced tests were performed in Ukraine for the public health fund.

Operating profit (EBIT) increased to EUR 26.8 million (EUR 22.0 million), a margin of 13.4% (12.1%), strong performance supported by Germany and the acquisition in Q2 2025.

EBITDA was EUR 41.7 million (EUR 35.9 million), an EBITDA margin of 20.8% (19.7%).

EBITDAaL was EUR 33.4 million (EUR 28.7 million), a margin of 16.7% (15.7%).

The segment delivered solid performance, supported primarily by Germany, where positive FFS momentum continued and by the acquisition in Q2 2025, this despite adverse weather conditions and power outages in key markets. Overall profit contribution increased driven by pricing initiatives and volume growth. 

Revenue from external customers, recognised over time as services are rendered, by payer and by country is disclosed in the following table.